Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

Completed · Phase 1/Phase 2

Conditions studied: Epistaxis, Hereditary Hemorrhagic Telangiectasia

In brief

The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.

Key facts

Study ID

NCT01408732

Run by

University of Minnesota

People needed

18

Starts

2011-02-01

Expected to finish

2014-09-01

Last updated by the study team

2019-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• a clinical diagnosis of HHT based on the Curacoa Criteria
• age 18 and older
• cognitive ability and willingness to sign the study consent form and complete the study forms and questionnaires

You may not qualify if…

• previous sclerotherapy with Sodium Tetradecyl Sulfate

Where it is running

• University of Minnesota Otolaryngology Clinic — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.